Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2011 1
2018 2
2020 2
2021 7
2022 3
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
Rubino M, Di Stasio GD, Bodei L, Papi S, Rocca PA, Ferrari ME, Fodor CI, Bagnardi V, Frassoni S, Mei R, Fazio N, Ceci F, Grana CM. Rubino M, et al. Among authors: mei r. Endocrine. 2024 May;84(2):704-710. doi: 10.1007/s12020-024-03707-5. Epub 2024 Feb 7. Endocrine. 2024. PMID: 38324106
68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study.
Mei R, Kessler L, Pabst KM, Weber M, Schmidkonz C, Rischpler C, Zacho HD, Hope T, Schwarzenböck SM, Allen-Auerbach M, Emmett L, Ferdinandus J, Unterrainer M, Schaarschmidt BM, Umutlu L, Farolfi A, Castellucci P, Nanni C, Telo S, Fanti S, Herrmann K, Fendler WP. Mei R, et al. J Nucl Med. 2023 Jul;64(7):1043-1048. doi: 10.2967/jnumed.122.265245. Epub 2023 May 25. J Nucl Med. 2023. PMID: 37230530
PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment.
Bianchi L, Ceci F, Balestrazzi E, Costa F, Droghetti M, Piazza P, Pissavini A, Presutti M, Farolfi A, Mei R, Castellucci P, Gandaglia G, Larcher A, Robesti D, Mottrie A, Briganti A, Morganti AG, Fanti S, Montorsi F, Schiavina R, Brunocilla E. Bianchi L, et al. Among authors: mei r. Cancers (Basel). 2023 Mar 29;15(7):2027. doi: 10.3390/cancers15072027. Cancers (Basel). 2023. PMID: 37046687 Free PMC article.
Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with 68Ga-PSMA PET/CT Features in Primary Staging.
Vetrone L, Mei R, Bianchi L, Giunchi F, Farolfi A, Castellucci P, Droghetti M, Presutti M, Degiovanni A, Schiavina R, Brunocilla E, D'Errico A, Fanti S. Vetrone L, et al. Among authors: mei r. Cancers (Basel). 2023 Mar 10;15(6):1716. doi: 10.3390/cancers15061716. Cancers (Basel). 2023. PMID: 36980602 Free PMC article.
Case report: PSMA PET/CT addresses the correct diagnosis in a patient with metastatic prostate cancer despite negative core biopsies and mpMRI. A diagnostic challenge.
Vetrone L, Cuzzani G, Mei R, Zanoni L, Bertaccini A, Bianchi L, Castellucci P, Gaudiano C, Cappelli A, Giunchi F, Fanti S. Vetrone L, et al. Among authors: mei r. Front Oncol. 2023 Feb 7;13:1101221. doi: 10.3389/fonc.2023.1101221. eCollection 2023. Front Oncol. 2023. PMID: 36824128 Free PMC article.
The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence.
Bianchi L, Ceci F, Costa F, Balestrazzi E, Droghetti M, Piazza P, Pissavini A, Mei R, Farolfi A, Castellucci P, Puliatti S, Larcher A, Gandaglia G, Robesti D, Mottrie A, Briganti A, Morganti AG, Fanti S, Montorsi F, Schiavina R, Brunocilla E. Bianchi L, et al. Among authors: mei r. Cancers (Basel). 2022 Dec 30;15(1):247. doi: 10.3390/cancers15010247. Cancers (Basel). 2022. PMID: 36612242 Free PMC article.
22 results